Retatrutide 10mg

What Was Retatrutide?

Retatrutide was an advanced peptide studied for its powerful effects on weight management and metabolic health through triple hormone receptor activation.

It worked by activating three key pathways at once — GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Together, these systems influence appetite, blood sugar, fat metabolism, and energy use.

In research, Retatrutide was used to explore the biological mechanisms behind obesity, insulin resistance, fatty liver disease, and cardiometabolic disorders, offering valuable insight into how multiple hormone signals interact to regulate energy balance.

Clinical Trial Results

Retatrutide attracted global attention after phase II clinical trials showed unprecedented weight-loss results.

In these studies, participants achieved average body-weight reductions of up to 24% over 48–72 weeks, with some losing even more. This represented the most significant reduction ever reported for an incretin-based compound.

Beyond weight loss, research showed broad metabolic improvements, including:

• Better insulin sensitivity – the body used insulin more effectively.

• Improved blood sugar control, including lower fasting glucose levels.

• Reduced HbA1c – a marker of average blood sugar over several months, improving by up to 2.2 percentage points.

• Higher resting energy expenditure – the body burned more calories at rest.

• Increased fat oxidation – greater use of stored fat for energy.

• Reduced liver fat and improved cholesterol balance.

• Better cardiovascular health, including lower blood pressure and improved lipid ratios.

These results placed Retatrutide at the forefront of modern metabolic research.

Dosing Used in Clinical Studies

In clinical studies, Retatrutide was given once weekly by subcutaneous injection — meaning it was injected under the skin, typically in the abdomen, thigh, or upper arm.

Researchers increased the dose gradually over time to help participants adapt and reduce side effects.

The typical research dosing schedule was:

• Started at: 2 mg per week for the first 4 weeks

• Then increased to: 4 mg per week

• Most participants continued at: 8–12 mg per week (depending on the study phase)

These dose levels reflected what was used in controlled research environments to study the compound’s safety and effects.

How Retatrutide Worked

Retatrutide’s unique triple mechanism activated GLP-1, GIP, and glucagon receptors at the same time. This produced combined effects on multiple body systems:

• GLP-1 activation: reduced hunger, increased fullness, and improved insulin secretion.

• GIP activation: enhanced insulin release and supported fat metabolism.

• Glucagon activation: increased calorie burning and promoted fat breakdown.

Together, these actions triggered a strong thermogenic (heat-producing) and metabolic response, leading to sustained fat loss, better blood sugar control, and improved energy balance.

Study Highlights

Across major studies:

• Participants lost 20–24% of body weight on average over 12–16 months, with some losing more.

• HbA1c (average blood sugar) improved by up to 2.2 percentage points.

• Participants reported less hunger and higher energy levels.

• Liver fat and deep abdominal fat were significantly reduced.

• Cholesterol, triglycerides, and blood pressure all improved.

These results made Retatrutide the most advanced and effective incretin-based research compound studied to date.

Shipping, Storage, and Reconstitution

Each Retatrutide vial was packaged securely to ensure product stability during shipping.
The dry (lyophilized) peptide powder was stored in a cool, dry place away from light. For long-term storage, it was kept refrigerated or frozen.

Before research use, the powder was mixed with sterile bacteriostatic water to form a solution. After reconstitution, the solution was stored at 2–8 °C and used within standard laboratory timeframes.

For research use only – not for human or veterinary use.